Skip to main content
Top
Published in: Journal of Translational Medicine 1/2019

Open Access 01-12-2019 | NSCLC | Research

Genome-wide profiling reveals alternative polyadenylation of mRNA in human non-small cell lung cancer

Authors: Shirong Zhang, Xiaochen Zhang, Wei Lei, Jiafeng Liang, Yasi Xu, Hailiang Liu, Shenglin Ma

Published in: Journal of Translational Medicine | Issue 1/2019

Login to get access

Abstract

Background

Lung cancer is the second most common cancer with an extremely poor overall survival rate. Post-transcriptional regulation of gene expression play many important roles in human cancer, and one of the potential mechanisms underlying this is alternative mRNA maturation at its 3′ untranslated regions (3′-UTRs).

Methods

Cancer tissues and paired adjacent normal lung tissues from 26 patients diagnosed with non-small cell lung cancer (NSCLC) were analyzed by in vitro transcription-sequencing alternative polyadenylation sites (IVT-SAPAS). 41,773,101 reads in average were obtained from each paired sample. A potential regulation of Cleavage Stimulation Factor Subunit 2 (CSTF2) on 3′UTR length of genes was tested in H460 cells.

Results

1439 (10.26%) genes showed up-regulated expression and 1364 (9.72%) genes showed down-regulated expression in lung cancer tissue versus normal lung tissue, and shorten 3′UTR in cancer tissue was detected in cancer tissues collected from 96.2% (25/26) patients, indicating lung cancer tend to have shortened 3′UTRs of these identified genes. KEGG analysis showed 1855 genes with shorten 3′UTR were enriched in mTOR signaling, ubiquitin mediated proteolysis and RNA degradation. Knocking down CSTF2 expression in H460 cells results in 3′UTR elongation of genes that was identified to be with shortened length in cancer tissues.

Conclusion

Alternative polyadenylation (APA) site-switching of 3′UTRs is prevalent in NSCLC, and CSTF2 may serve as an oncogene regulates the 3′UTR length of cancer related genes in NSCLC.
Appendix
Available only for authorised users
Literature
1.
go back to reference Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 2018;68(1):7–30.CrossRef Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 2018;68(1):7–30.CrossRef
2.
go back to reference Lantuejoul S, et al. New WHO classification of lung adenocarcinoma and preneoplasia. Ann Pathol. 2016;36(1):5–14.CrossRef Lantuejoul S, et al. New WHO classification of lung adenocarcinoma and preneoplasia. Ann Pathol. 2016;36(1):5–14.CrossRef
3.
go back to reference Molina JR, et al. Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. Mayo Clin Proc. 2008;83(5):584–94.CrossRef Molina JR, et al. Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. Mayo Clin Proc. 2008;83(5):584–94.CrossRef
4.
go back to reference Zappa C, Mousa SA. Non-small cell lung cancer: current treatment and future advances. Transl Lung Cancer Res. 2016;5(3):288–300.CrossRef Zappa C, Mousa SA. Non-small cell lung cancer: current treatment and future advances. Transl Lung Cancer Res. 2016;5(3):288–300.CrossRef
5.
go back to reference Rowley JD. Chromosome translocations: dangerous liaisons revisited. Nat Rev Cancer. 2001;1(3):245–50.CrossRef Rowley JD. Chromosome translocations: dangerous liaisons revisited. Nat Rev Cancer. 2001;1(3):245–50.CrossRef
6.
go back to reference Mayr C, Bartel DP. Widespread shortening of 3′UTRs by alternative cleavage and polyadenylation activates oncogenes in cancer cells. Cell. 2009;138(4):673–84.CrossRef Mayr C, Bartel DP. Widespread shortening of 3′UTRs by alternative cleavage and polyadenylation activates oncogenes in cancer cells. Cell. 2009;138(4):673–84.CrossRef
7.
go back to reference Proudfoot NJ. Ending the message: poly(A) signals then and now. Genes Dev. 2011;25(17):1770–82.CrossRef Proudfoot NJ. Ending the message: poly(A) signals then and now. Genes Dev. 2011;25(17):1770–82.CrossRef
8.
go back to reference Chan S, Choi EA, Shi Y. Pre-mRNA 3′-end processing complex assembly and function. Wiley Interdiscip Rev RNA. 2011;2(3):321–35.CrossRef Chan S, Choi EA, Shi Y. Pre-mRNA 3′-end processing complex assembly and function. Wiley Interdiscip Rev RNA. 2011;2(3):321–35.CrossRef
9.
go back to reference Danckwardt S, Hentze MW, Kulozik AE. 3′ end mRNA processing: molecular mechanisms and implications for health and disease. EMBO J. 2008;27(3):482–98.CrossRef Danckwardt S, Hentze MW, Kulozik AE. 3′ end mRNA processing: molecular mechanisms and implications for health and disease. EMBO J. 2008;27(3):482–98.CrossRef
10.
go back to reference Yeh HS, Yong J. Alternative polyadenylation of mRNAs: 3′-untranslated region matters in gene expression. Mol Cells. 2016;39(4):281–5.CrossRef Yeh HS, Yong J. Alternative polyadenylation of mRNAs: 3′-untranslated region matters in gene expression. Mol Cells. 2016;39(4):281–5.CrossRef
11.
go back to reference Chen W, et al. Alternative polyadenylation: methods, findings, and impacts. Genom Proteom Bioinf. 2017;15(5):287–300.CrossRef Chen W, et al. Alternative polyadenylation: methods, findings, and impacts. Genom Proteom Bioinf. 2017;15(5):287–300.CrossRef
12.
go back to reference Fu Y, et al. Differential genome-wide profiling of tandem 3′ UTRs among human breast cancer and normal cells by high-throughput sequencing. Genome Res. 2011;21(5):741–7.CrossRef Fu Y, et al. Differential genome-wide profiling of tandem 3′ UTRs among human breast cancer and normal cells by high-throughput sequencing. Genome Res. 2011;21(5):741–7.CrossRef
13.
go back to reference Lembo A, Di Cunto F, Provero P. Shortening of 3′UTRs correlates with poor prognosis in breast and lung cancer. PLoS ONE. 2012;7(2):e31129.CrossRef Lembo A, Di Cunto F, Provero P. Shortening of 3′UTRs correlates with poor prognosis in breast and lung cancer. PLoS ONE. 2012;7(2):e31129.CrossRef
14.
go back to reference Ichinose J, et al. Alternative polyadenylation is associated with lower expression of PABPN1 and poor prognosis in non-small cell lung cancer. Cancer Sci. 2014;105(9):1135–41.CrossRef Ichinose J, et al. Alternative polyadenylation is associated with lower expression of PABPN1 and poor prognosis in non-small cell lung cancer. Cancer Sci. 2014;105(9):1135–41.CrossRef
15.
go back to reference Fu Y, et al. IVT-SAPAS: low-input and rapid method for sequencing alternative polyadenylation sites. PLoS ONE. 2015;10(12):e0145477.CrossRef Fu Y, et al. IVT-SAPAS: low-input and rapid method for sequencing alternative polyadenylation sites. PLoS ONE. 2015;10(12):e0145477.CrossRef
16.
go back to reference Langmead B, et al. Ultrafast and memory-efficient alignment of short DNA sequences to the human genome. Genome Biol. 2009;10(3):R25.CrossRef Langmead B, et al. Ultrafast and memory-efficient alignment of short DNA sequences to the human genome. Genome Biol. 2009;10(3):R25.CrossRef
17.
go back to reference Matoulkova E, et al. The role of the 3′ untranslated region in post-transcriptional regulation of protein expression in mammalian cells. RNA Biol. 2012;9(5):563–76.CrossRef Matoulkova E, et al. The role of the 3′ untranslated region in post-transcriptional regulation of protein expression in mammalian cells. RNA Biol. 2012;9(5):563–76.CrossRef
18.
go back to reference Erson-Bensan AE, Can T. Alternative polyadenylation: another foe in cancer. Mol Cancer Res. 2016;14(6):507–17.CrossRef Erson-Bensan AE, Can T. Alternative polyadenylation: another foe in cancer. Mol Cancer Res. 2016;14(6):507–17.CrossRef
19.
go back to reference Kowalczuk O, et al. Lymphatics-associated genes are downregulated at transcription level in non-small cell lung cancer. Oncol Lett. 2018;15(5):6752–62.PubMedPubMedCentral Kowalczuk O, et al. Lymphatics-associated genes are downregulated at transcription level in non-small cell lung cancer. Oncol Lett. 2018;15(5):6752–62.PubMedPubMedCentral
20.
go back to reference Ugorski M, Dziegiel P, Suchanski J. Podoplanin—a small glycoprotein with many faces. Am J Cancer Res. 2016;6(2):370–86.PubMedPubMedCentral Ugorski M, Dziegiel P, Suchanski J. Podoplanin—a small glycoprotein with many faces. Am J Cancer Res. 2016;6(2):370–86.PubMedPubMedCentral
21.
go back to reference Gao X, et al. MAP4K4 is a novel MAPK/ERK pathway regulator required for lung adenocarcinoma maintenance. Mol Oncol. 2017;11(6):628–39.CrossRef Gao X, et al. MAP4K4 is a novel MAPK/ERK pathway regulator required for lung adenocarcinoma maintenance. Mol Oncol. 2017;11(6):628–39.CrossRef
22.
go back to reference Millevoi S, Vagner S. Molecular mechanisms of eukaryotic pre-mRNA 3′ end processing regulation. Nucleic Acids Res. 2010;38(9):2757–74.CrossRef Millevoi S, Vagner S. Molecular mechanisms of eukaryotic pre-mRNA 3′ end processing regulation. Nucleic Acids Res. 2010;38(9):2757–74.CrossRef
23.
go back to reference Natalizio BJ, Wente SR. Postage for the messenger: designating routes for nuclear mRNA export. Trends Cell Biol. 2013;23(8):365–73.CrossRef Natalizio BJ, Wente SR. Postage for the messenger: designating routes for nuclear mRNA export. Trends Cell Biol. 2013;23(8):365–73.CrossRef
24.
go back to reference Jalkanen AL, Coleman SJ, Wilusz J. Determinants and implications of mRNA poly(A) tail size—does this protein make my tail look big? Semin Cell Dev Biol. 2014;34:24–32.CrossRef Jalkanen AL, Coleman SJ, Wilusz J. Determinants and implications of mRNA poly(A) tail size—does this protein make my tail look big? Semin Cell Dev Biol. 2014;34:24–32.CrossRef
25.
go back to reference Kumar GR, Glaunsinger BA. Nuclear import of cytoplasmic poly(A) binding protein restricts gene expression via hyperadenylation and nuclear retention of mRNA. Mol Cell Biol. 2010;30(21):4996–5008.CrossRef Kumar GR, Glaunsinger BA. Nuclear import of cytoplasmic poly(A) binding protein restricts gene expression via hyperadenylation and nuclear retention of mRNA. Mol Cell Biol. 2010;30(21):4996–5008.CrossRef
26.
go back to reference Bresson SM, Conrad NK. The human nuclear poly(a)-binding protein promotes RNA hyperadenylation and decay. PLoS Genet. 2013;9(10):e1003893.CrossRef Bresson SM, Conrad NK. The human nuclear poly(a)-binding protein promotes RNA hyperadenylation and decay. PLoS Genet. 2013;9(10):e1003893.CrossRef
27.
go back to reference Mandel CR, Bai Y, Tong L. Protein factors in pre-mRNA 3′-end processing. Cell Mol Life Sci. 2008;65(7–8):1099–122.CrossRef Mandel CR, Bai Y, Tong L. Protein factors in pre-mRNA 3′-end processing. Cell Mol Life Sci. 2008;65(7–8):1099–122.CrossRef
28.
go back to reference Zhao J, Hyman L, Moore C. Formation of mRNA 3′ ends in eukaryotes: mechanism, regulation, and interrelationships with other steps in mRNA synthesis. Microbiol Mol Biol Rev. 1999;63(2):405–45.PubMedPubMedCentral Zhao J, Hyman L, Moore C. Formation of mRNA 3′ ends in eukaryotes: mechanism, regulation, and interrelationships with other steps in mRNA synthesis. Microbiol Mol Biol Rev. 1999;63(2):405–45.PubMedPubMedCentral
29.
go back to reference Wilusz J, Shenk T. A uridylate tract mediates efficient heterogeneous nuclear ribonucleoprotein C protein-RNA cross-linking and functionally substitutes for the downstream element of the polyadenylation signal. Mol Cell Biol. 1990;10(12):6397–407.CrossRef Wilusz J, Shenk T. A uridylate tract mediates efficient heterogeneous nuclear ribonucleoprotein C protein-RNA cross-linking and functionally substitutes for the downstream element of the polyadenylation signal. Mol Cell Biol. 1990;10(12):6397–407.CrossRef
30.
go back to reference Takagaki Y, et al. A multisubunit factor, CstF, is required for polyadenylation of mammalian pre-mRNAs. Genes Dev. 1990;4(12A):2112–20.CrossRef Takagaki Y, et al. A multisubunit factor, CstF, is required for polyadenylation of mammalian pre-mRNAs. Genes Dev. 1990;4(12A):2112–20.CrossRef
31.
go back to reference Wilusz J, Shenk T. A 64 kd nuclear protein binds to RNA segments that include the AAUAAA polyadenylation motif. Cell. 1988;52(2):221–8.CrossRef Wilusz J, Shenk T. A 64 kd nuclear protein binds to RNA segments that include the AAUAAA polyadenylation motif. Cell. 1988;52(2):221–8.CrossRef
32.
go back to reference Takagaki Y, Manley JL. Complex protein interactions within the human polyadenylation machinery identify a novel component. Mol Cell Biol. 2000;20(5):1515–25.CrossRef Takagaki Y, Manley JL. Complex protein interactions within the human polyadenylation machinery identify a novel component. Mol Cell Biol. 2000;20(5):1515–25.CrossRef
33.
go back to reference Yao C, et al. Transcriptome-wide analyses of CstF64-RNA interactions in global regulation of mRNA alternative polyadenylation. Proc Natl Acad Sci USA. 2012;109(46):18773–8.CrossRef Yao C, et al. Transcriptome-wide analyses of CstF64-RNA interactions in global regulation of mRNA alternative polyadenylation. Proc Natl Acad Sci USA. 2012;109(46):18773–8.CrossRef
Metadata
Title
Genome-wide profiling reveals alternative polyadenylation of mRNA in human non-small cell lung cancer
Authors
Shirong Zhang
Xiaochen Zhang
Wei Lei
Jiafeng Liang
Yasi Xu
Hailiang Liu
Shenglin Ma
Publication date
01-12-2019
Publisher
BioMed Central
Published in
Journal of Translational Medicine / Issue 1/2019
Electronic ISSN: 1479-5876
DOI
https://doi.org/10.1186/s12967-019-1986-0

Other articles of this Issue 1/2019

Journal of Translational Medicine 1/2019 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.